Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Notified -
Globe Newswire9-12-2025, 20:00
Sea Index CO2 certification for superyachts earns Capenergies Label 10-06-2024, 20:11